Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Multiplex Assay Kit for Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay)
CXCL7; PPBP; PBP; B-TG1; CTAP-III; CTAP3; CTAPIII; LA-PF4; LDGF; MDGF; NAP2; SCYB7; TC1; TC2; TGB1; THBGB1; Pro-Platelet Basic Protein; Beta-Thromboglobulin
(Note: Up to 8-plex in one testing reaction)
- Product No.LMA370Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.2-200pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.067 pg/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 348
US$ 362
US$ 382
US$ 409
US$ 436
US$ 476
US$ 536
US$ 670
Add to Price Calculator
Result
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 80-89 | 84 |
| EDTA plasma(n=5) | 97-104 | 101 |
| heparin plasma(n=5) | 86-101 | 96 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Chemokine (C-X-C motif) ligand 7 ( CXCL7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 78-101% | 95-103% | 82-101% | 81-104% |
| EDTA plasma(n=5) | 87-95% | 88-102% | 89-103% | 93-102% |
| heparin plasma(n=5) | 78-101% | 98-105% | 86-98% | 91-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#: CXCL7) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Clinical Hemorheology and Microcirculation | Strict heart rate control attenuates prothrombotic state and platelet activity in patients with non-valvular permanent atrial fibrillation. Pubmed: 2347822 |
| International Journal of Pharma & Bio Sciences | STUDIES ON THE STORAGE OF POOLED PLATELETS IN NON DOP PVC CONTAINERS Ebscohost: Source |
| Journal of Affective Disorders | Bioprofiling of platelets in medicated patients with depression. Pubmed:25451399 |
| Perfusion | Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testing PubMed: 26243277 |
| Physiol Behav | Differential changes in platelet reactivity induced by acute physical compared to persistent mental stress PubMed: 26192713 |
| J Affect Disord | Bioprofiling of platelets in medicated patients with depression PubMed: 25451399 |
| Turk Kardiyol Dern Ars | Markers of coagulation and fibrinolysis do not detect or predict the presence of left atrial appendage thrombus in patients with atrial fibrillation Pubmed: 32147650 |
| JOURNAL OF FOOD BIOCHEMISTRY | A novel di‐peptide Met‐Glu from collagen hydrolysates inhibits platelet aggregation and thrombus formation via regulation of Gq‐mediated signaling Pubmed: 32662128 |
| Membranes (Basel) | Endogenous Nitric Oxide-Releasing Microgel Coating Prevents Clot Formation on Oxygenator Fibers Exposed to In Vitro Blood Flow Pubmed:35054599 |
| Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats Pubmed:35183388 |